Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
Tag: durvalumumab
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in
